Novo's CagriSema Delivers 25% Weight Loss in Women in Late-Stage Trial

Novo Nordisk says its experimental CagriSema injection achieved 25% weight loss in women in a late-stage analysis, topping the results of its blockbuster obesity drug Wegovy.